Table 4.
Effects of treatment on resolution of influenza symptoms, resolution of illness, and return to school or normal activities
| Study | Median days to resolution or alleviation of symptoms | Median days to resolution of illness* | Days to return to school/normal activities | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Antiviral | Control | Difference (95%CI) | Antiviral | Control | Difference (95%CI) | Antiviral | Control | Difference (95%CI) | |||
| Confirmed influenza | |||||||||||
| Zanamivir: | |||||||||||
| NAI30009w2 | 4.0 | 5.25 | 1.25 (0.5 to 2.0), P<0.001 | — | — | — | NR | NR | 1 day (NA), P=0.022 | ||
| NAI30028w1 | 5.0 | 5.5 | 0.5 (NA), P=NA | — | — | — | 36% (62/172) at day 5 | 28% (25/89) at day 5 | RD=0.08 (0.04 to 0.20), P=0.19 | ||
| Oseltamivir: | |||||||||||
| WV15758w3 | 2.6 | 4.2 | 1.5 (NA) P<0.001 | 4.2 | 5.7 | 1.5 (0.3 to 2.5), P<0.001 | NR | NR | NR | ||
| WV15759/ WV15871w4 |
3.8 | 4.8 | 1.1 (NA), P=0.12 | 5.2 | 5.6 | 0.4 (NA), P=0.54 | 4.2† | 4.8† | 0.5 (NA), P=0.46 | ||
| Clinical influenza | |||||||||||
| Zanamivir: | |||||||||||
| NAI30009w2 | 4.5 | 5.0 | 0.5 (0.0 to 1.5), P=0.011 | — | — | — | NR | NR | 1 day (NA), P=0.019 | ||
| NAI30028w1 | — | — | — | — | — | — | — | — | — | ||
| Oseltamivir: | |||||||||||
| WV15758w3 | NR | NR | NR | 4.4 | 5.3 | 0.9 (0.2 to 1.9), P<0.001 | NR | NR | NR | ||
| WV15759/WV15871w4 | NR | NR | NR | NR | NR | NR | NR | NR | NR | ||
RD=risk difference; NR=outcome assessed in study but not results not reported; NA=not available.
*Defined as alleviation of symptoms + return to normal activities + afebrile.
†Median.